AVN-211

AVN-211 (CD-008-0173) is a drug which acts as a highly selective 5-HT6 receptor antagonist and is under development by Avineuro Pharmaceuticals for the treatment of schizophrenia.[1][2][3] In early 2011, it successfully completed phase IIa clinical trials,[1][4] with benefits on positive symptoms and some procognitive effects observed,[5] and in mid 2013, phase IIb clinical trials for schizophrenia began.[6] Avineuro Pharmaceuticals has also expressed intention to start clinical trials of AVN-211 for Alzheimer's disease in 2015.[6][7]

AVN-211
Clinical data
Other namesCD-008-0173
Identifiers
IUPAC name
  • 5,7-dimethyl-2-(methylsulfanyl)-3-(phenylsulfonyl)pyrazolo[1,5-a]pyrimidine
CAS Number
ChemSpider
ChEMBL
Chemical and physical data
FormulaC15H15N3O2S2
Molar mass333.42 g·mol−1
3D model (JSmol)
SMILES
  • Cc1cc(n2c(n1)c(c(n2)SC)S(=O)(=O)c3ccccc3)C
InChI
  • InChI=1S/C15H15N3O2S2/c1-10-9-11(2)18-14(16-10)13(15(17-18)21-3)22(19,20)12-7-5-4-6-8-12/h4-9H,1-3H3
  • Key:KSAUCBGUWGWPDL-UHFFFAOYSA-N

See also

References
  1. Sylvain Celanire; Sonia Poli (13 October 2014). Small Molecule Therapeutics for Schizophrenia. Springer. pp. 31, 37. ISBN 978-3-319-11502-3.
  2. Pharmacology of 5-HT6 receptors. Academic Press. 7 December 2010. pp. 164–. ISBN 978-0-12-384977-9.
  3. "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
  4. "Avineuro Pharmaceuticals, Inc. Reports positive Phase 2a clinical proof of concept trial results on AVN-211, potent small molecule for treatment of schizophrenia. « Welcome to Avineuro Pharmaceuticals, Inc".
  5. Morozova MA, Lepilkina TA, Rupchev GE, Beniashvily AG, Burminskiy DS, Potanin SS, et al. (August 2014). "Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study". CNS Spectrums. 19 (4): 316–23. doi:10.1017/S1092852913000394. PMID 23768250. S2CID 25486838.
  6. "Avineuro Pharmaceuticals, Inc. Announces beginning of Phase 2b clinical studies of AVN-211, potent small molecule for treatment of schizophrenia. « Welcome to Avineuro Pharmaceuticals, Inc".
  7. Ivachtchenko AV, Lavrovsky Y, Ivanenkov YA (March 2016). "AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer's Disease". Molecular Pharmaceutics. 13 (3): 945–63. doi:10.1021/acs.molpharmaceut.5b00830. PMID 26886442.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.